Condition: Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer · Advanced Solid Tumors Harboring the KRAS G12C Mutation · Sponsor: Novartis Pharmaceuticals
The purpose of this study is to allow continued access to opnurasib (JDQ443) to participants who are benefitting from treatment with opnurasib as a single agent or in combination with other study treatments in pre-defined Novartis-sponsored opnurasib studies and to continue to assess safety in these participants.
This description comes directly from the study's public registry record.
Novartis Pharmaceuticals · +41613241111 · novartis.email@novartis.com
Novartis Pharmaceuticals · +81337978748 · novartis.email@novartis.com
Always discuss trial participation with your own doctor first.
| Novartis Investigative Site | Sint-Niklaas, Oost Vlaanderen, Belgium | Recruiting |
| Novartis Investigative Site | Montreal, Quebec, Canada | Recruiting |
| Novartis Investigative Site | Guangzhou, Guangdong, China | Recruiting |
| Novartis Investigative Site | Kashiwa, Chiba, Japan | Recruiting |
| Novartis Investigative Site | Koto Ku, Tokyo, Japan | Recruiting |
| Novartis Investigative Site | Kuching, Sarawak, Malaysia | Recruiting |
| Novartis Investigative Site | Seoul, South Korea | Active Not Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07468071